Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Blood (2014) 124 (21): 76.

https://doi.org/10.1182/blood.V124.21.76.76

Published: 2014

Journal Articles

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

Gillian G. Johnson, Ke Lin, Trevor F. Cox, Melanie Oates, David R. Sibson, Richard Eccles, Bryony Lloyd, Laura-Jayne Gardiner, Daniel F. Carr, Munir Pirmohamed, Jonathan C. Strefford, David G. Oscier, David Gonzalez de Castro, Monica Else, Daniel Catovsky, Andrew R. Pettitt

Blood (2013) 122 (26): 4253–4258.

https://doi.org/10.1182/blood-2013-07-516666

Published: 2013

Includes: Supplemental data

Journal Articles

A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort

Martin F. Kaiser, MD, Dil Begum, BSc, Paula Proszek, MSc, Nasrin Dahir, BSc, David Gonzalez de Castro, PhD, Charlotte Pawlyn, MD, Annamaria Brioli, MD, Suvi Savola, PhD, Walter Gregory, PhD, Roger G. Owen, MD, Graham H. Jackson, MD, Faith E Davies, MD, Brian A Walker, PhD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 3097.

https://doi.org/10.1182/blood.V122.21.3097.3097

Published: 2013

Journal Articles

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

David G. Oscier, Matthew J. J. Rose-Zerilli, Nils Winkelmann, David Gonzalez de Castro, Belen Gomez, Jade Forster, Helen Parker, Anton Parker, Anne Gardiner, Andrew Collins, Monica Else, Nicholas C. P. Cross, Daniel Catovsky, Jonathan C. Strefford

Blood (2013) 121 (3): 468–475.

https://doi.org/10.1182/blood-2012-05-429282

Published: 2013

Includes: Supplemental data

Journal Articles

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

Anton Parker, Jade Forster, Stacey Reichter, David Gonzalez de Castro, PhD, Daniel Catovsky, MD, David Oscier, MD

Blood (2011) 118 (21): 3884.

https://doi.org/10.1182/blood.V118.21.3884.3884

Published: 2011

Journal Articles

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

Andrew S. Moore, MBBS, FRACP, Amir Faisal, Vassilios Bavetsias, David Gonzalez de Castro, PhD, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, Sian Avery, Andrew DJ Pearson, Paul Workman, Julian Blagg, Florence I Raynaud, Suzanne A Eccles, Spiros Linardopoulos

Blood (2011) 118 (21): 3492.

https://doi.org/10.1182/blood.V118.21.3492.3492

Published: 2011

Journal Articles

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

Tina Bagratuni, Ping Wu, David Gonzalez de Castro, Emma L. Davenport, Nicholas J. Dickens, Brian A. Walker, Kevin Boyd, David C. Johnson, Walter Gregory, Gareth J. Morgan, Faith E. Davies

Blood (2010) 116 (2): 250–253.

https://doi.org/10.1182/blood-2010-01-263236

Published: 2010

Journal Articles

Loss of Non-Inherited Maternal MHC and Materno-Fetal Transmission of p190 Type BCR-ABL Leukemia.

Takeshi Isoda, Anthony Ford, Daisuke Tomizawa, Frederik W van Delft, David Gonzalez de Castro, Noriko Mitsuiki, Joannah Score, Tomohiko Taki, Tomohiro Morio, Masatoshi Takagi, Hiroh Saji, Shuki Mizutani, Mel Greaves

Blood (2009) 114 (22): 980.

https://doi.org/10.1182/blood.V114.22.980.980

Published: 2009

Journal Articles

Specific JAK2 mutation ( JAK2 R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

Lyndal Kearney, David Gonzalez De Castro, Jenny Yeung, Julia Procter, Sharon W. Horsley, Minenori Eguchi-Ishimae, Caroline M. Bateman, Kristina Anderson, Tracy Chaplin, Bryan D. Young, Christine J. Harrison, Helena Kempski, Chi Wai E. So, Anthony M. Ford, Mel Greaves

Blood (2009) 113 (3): 646–648.

https://doi.org/10.1182/blood-2008-08-170928

Published: 2009

Includes: Supplemental data

Journal Articles

XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.

Tina Bagratuni, Ping Wu, David Gonzalez de Castro, Emma L Davenport, Brian A Walker, Matthew W Jenner, David C Johnson, Gareth J. Morgan, Faith E Davies

Blood (2008) 112 (11): 1686.

https://doi.org/10.1182/blood.V112.11.1686.1686

Published: 2008

Journal Articles

Acquired Genetic Abnormalities in Acute Lymphoblastic Leukaemia in Patients with Down Syndrome.

Lyndal Kearney, Sharon W. Horsley, Caroline M. Bateman, David Gonzalez De Castro, Bryan D. Young, Tracy Chaplin, Minenori Eguchi, Mel Greaves

Blood (2007) 110 (11): 984.

https://doi.org/10.1182/blood.V110.11.984.984

Published: 2007

Journal Articles

The Impact of T h 1/T h 2 Response Variations on Risk of Developing Childhood Leukaemia: A Pilot Study.

Zara M. Josephs, PhD, David Gonzalez de Castro, PhD, David C. Johnson, B.Sc, Astrid Novosel, MD, Arndt Borkhardt, Pr, Katherine Pritchard-Jones, Mel F. Greaves

Blood (2005) 106 (11): 849.

https://doi.org/10.1182/blood.V106.11.849.849

Published: 2005

Journal Articles

Molecular Characterization in Hairy Cell Leukemia (HCL): Rearrangement Analysis of Heavy Chain in Immunoglobulin Genes (IgH).

Patricia Martín-Jiménez, Miguel Alcoceba, Maria E. Sarasquete, Ana Balanzategui, David Gonzalez de Castro, Maria C. Chillón, J. A. Queizán, M. Barbón, F. Ortega, M. J. Peñarrubia, D. Borrego, M. Cabezudo, Lorena Blázquez, Adriana Armellini, Carina Fernández, Ramón García-Sanz, Marcos González, J.F. San Miguel

Blood (2004) 104 (11): 4798.

https://doi.org/10.1182/blood.V104.11.4798.4798

Published: 2004

NARROW

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

Loss of Non-Inherited Maternal MHC and Materno-Fetal Transmission of p190 Type BCR-ABL Leukemia.

Specific JAK2 mutation ( JAK2 R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.

Acquired Genetic Abnormalities in Acute Lymphoblastic Leukaemia in Patients with Down Syndrome.

The Impact of T h 1/T h 2 Response Variations on Risk of Developing Childhood Leukaemia: A Pilot Study.

Molecular Characterization in Hairy Cell Leukemia (HCL): Rearrangement Analysis of Heavy Chain in Immunoglobulin Genes (IgH).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only